Swetha Kambhampati, M.D.

Swetha Kambhampati, M.D., sees her calling as a physician as the perfect way to combine her love for science with her passion for service. She aims to provide compassionate care tailored to each patient's needs. As an oncologist/hematologist specializing in lymphoma, she has experience and expertise in novel immunotherapies, CAR T cell therapy and stem cell transplantation. Her research is focused on developing and evaluating novel immunotherapies and targeted therapies for the treatment of non-Hodgkin and Hodgkin lymphoma. She leads a variety of cutting-edge trials for lymphoma and collaborates with lymphoma basic scientists to identify biomarkers predictive of response and resistance to therapies, in an effort to better personalize treatments for patients.

Dr. Kambhampati received her medical degree from Stanford University and pursued her internal medicine residency training at Johns Hopkins Hospital and hematology/oncology fellowship at University of California San Francisco. She completed an advanced fellowship focusing on lymphoma at City of Hope prior to joining the faculty. She has many peer-reviewed scientific publications to her credit, including publications in top journals such as Blood, British Journal of Hematology, and Blood Cancer Journal. She was recognized by the American Society of Clinical Oncology with a Young Investigator Award and Conquer Cancer Merit Award, and she was chosen to be an American Society of Hematology Clinical Research Training Institute Scholar and Lymphoma Research Foundation Eric Cohen Distinguished Scholar.

When not treating patients or conducting research, Dr. Kambhampati enjoys singing, traveling, hiking, exploring new restaurants and spending time with family.

Awards

• 2023, Academy of Next Wave of Investigators in CLL and NHL, Bio Ascend

• 2023, Lymphoma Research Foundation Lymphoma Scientific Research Mentoring Program Eric Cohen Distinguished Scholar

• 2023, Lymphoma Research Foundation Lymphoma Scientific Research Mentoring Program Scholar

• 2022, ASCO Conquer Cancer Merit Award

• 2021-2022, FDA-AACR Oncology Educational Fellowship

• 2021-2022, ASCO Young Investigator Award

• 2021, ASH Research Training Award for Fellows Finalist

• 2021, Multiple Myeloma Research Foundation Research Fellow Award

• 2020, ASH Abstract Achievement Award

• 2020-2021, ASH Clinical Research Training Institute Scholar

• 2020, ASCO FDA Workshop Selected Candidate

• 2019, Society for Translational Oncology Fellows’ Forum Scholar

• 2019, ASCO/AACR Methods in Clinical Cancer Research Workshop Selected Attendee

• 2018, UCSF Hematology/Oncology Annual Research Retreat Best Poster Award

• 2011, Klingenstein Fellow

• 2010, All USA Today 2010 College Academic Team

• 2010, Rhodes Scholarship Finalist

• 2010, Phi Beta Kappa Society

• 2010, Merage American Dream Fellowship

• 2010, Sigma Xi Honor Society

• 2009-2010, Leaders in Global Health Transformation

• 2009, Amgen Research Scholar

• 2009, Student Leaders in Service: AmeriCorps “Education Award Only” Program

• 2009, National Society of Collegiate Scholars Exemplary Scholar Award

• 2009, Johnson and Johnson Bioengineering Research Award

• 2008-2009, Emerson Music Scholar

• 2006, Co-Guest Editor of Up Your Score: The Underground Guide to the SAT

Memberships

• 2021, American Society for Transplantation and Cellular Therapy
• 2018, American Society of Clinical Oncology
• 2018, American Society of Hematology
• 2013, American College of Physicians

• Kambhampati S, Herrera A, Rhee J. How to treat diffuse large B-cell lymphoma: Oncologic and Cardiovascular Considerations. JACC: CardioOncology. Accepted. 2023 June. PMID: 37397077
• Kambhampati S, Shumilov E, Saumoy M, Herrera AF, Tilly H, Lenz G, Thiruvengadam N. Cost-effectiveness of Polatuzumab Vedotin in Combination with Chemoimmunotherapy (Pola-R-CHP) in Previously Untreated Diffuse Large B-cell lymphoma in Germany. British Journal of Hematology. 2023 May. PMID: 37188351.
• Kambhampati S, Shouse G, Danilov A. Thinking “outside the germinal center”: re-educating T cells to combat follicular lymphoma.” Blood Review. 2023 May. PMID: 37173225.
• Ladbury C, Dandapani S, Hao C, Fabros M, Amini A, Sampath S, Glaser S, Sokolov K, Yeh J, Baird J, Kambhampati S, et al. Long term follow-up of bridging therapies prior to CAR T-cell therapy for relapsed/refractory large B-cell lymphoma. Cancers. 2023 March. PMID: 36980632.
• Torka P,* Kambhampati S,* Chen L, Wang X, Chen C, Vuong D Qin H, Muir A, Orand K, Borja I, Smith D, Herrera A, Spurgeon S, Park B, Lewis L, Hernandez-Ilizaliturri F, Xia Z, Danilov A. A Phase I trial of pevonedistat a Nedd8-activating enzyme inhibitor, plus ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Blood Cancer Journal. 2023 Jan. PMID: 36631449. * First two authors contributed equally and are co-first authors
• Kambhampati S, Herrera AF. Incorporating novel agents into frontline treatment of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program.  2022 Dec. PMID: 36485085.
• Kambhampati S, Zain J. ctDNA in Lymphoma. Current Hematologic Malignancy Reports. 2022 Dec. PMID: 36214943.
• Kambhampati S, Saumoy M, Schneider Y, Pak S, Budde L, Mei M, Popplewell L, Siddiqi T, Wen Y, Zain J, Forman S, Kwak L, Rosen S, Danilov A, Herrera A, Thiruvengadam N. Cost Effectiveness of Polatuzumab Vedotin Combined with Chemoimmunotherapy in Untreated Diffuse Large B-cell Lymphoma. Blood. 2022 Dec. PMID: 35700381.
• Kambhampati S, Saumoy M, Schneider Y, Serrao S, Solaimani P, Budde L, Mei M, Popplewell L, Siddiqi T, Zain J, Forman S, Kwak L, Rosen S, Danilov A, Herrera A, Thiruvengadam N. Cost Effectiveness of Second line Axicabtagene ciloleucel in Relapsed Refractory Diffuse Large B-cell Lymphoma. Blood. 2022 Nov. PMID: 35914220.
• Ladbury C,* Kambhampati S,* Othman T, Hao C, Chen L, Wong J, Cao T, Herrera A, Mei M, Dandapani S. Role of Salvage Radiation Treatment of Relapses in Relapsed/Refractory Diffuse Large B cell Lymphoma Post Autologous Stem Cell Transplant. International Journal Radiation Oncology, Biology, Physics. 2022 Jul. PMID: 35176414. *First two authors contributed equally and are co-first authors